Solveig Katrine Smedsland

Solveig Katrine Smedsland

Auto-generated profile, based on publicly available information

Solveig Katrine Smedsland

National Advisory Unit of Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SSSolveig K. Smedsland
Solveig K. Smedsland
KVKathrine F. Vandraas
Kathrine F. Vandraas
SBSynne K. Bøhn
Synne K. Bøhn
ADAlv A. Dahl
Alv A. Dahl
CKCecilie E. Kiserud
Cecilie E. Kiserud
KRKristin V. Reinertsen
Kristin V. Reinertsen
Purpose: Sexual health is a key quality of life issue. Knowledge concerning sexual health in long-term breast cancer survivors (BCSs) is limited. Within a nationwide sample, we aimed to assess the prevalence of sexual inactivity and to explore factors associated with sexual inactivity and reduced sexual functioning among long-term BCSs. Methods: Long-term BCSs aged 20–65 years when diagnosed with early-stage breast cancer in 2011–2012 were identified by the Cancer Registry of Norway in 2019 (n = 2803) and invited to participate in a nationwide survey. Sexual health was measured using the multidimensional Sexual Activity Questionnaire. Factors associated with sexual inactivity and reduced sexual functioning were explored using multivariable logistic- and linear regression analyses with adjustments for relevant sociodemographic, health-, and cancer-related variables. Results: The final sample consisted of 1307 BCSs with a mean age of 52 years at diagnosis. Fifty-two percent of the BCSs were sexually inactive. Lack of interest was the most common reason for sexual inactivity. Treatment with aromatase inhibitor (OR 1.73, 95% CI 1.23, 2.43) and poor body image (OR 0.99, 95% CI 0.99, 0.995) were associated with sexual inactivity. Among sexually active BCSs, depression (B − 1.04, 95% CI − 2.10, − 0.02) and physical inactivity (B − 0.61, 95% CI − 1.21, − 0.02) were inversely related to sexual pleasure. Treatment with aromatase inhibitor (B 0.61, 95% CI 0.20, 1.01), sleep problems (B 0.37, 95% CI 0.04, 0.70), breast symptoms (B 0.01, 95% CI 0.003, 0.02), and chronic fatigue (B 0.43, 95% CI 0.05, 0.81) were associated with sexual discomfort. Chemotherapy (OR 1.91, 95% CI 1.23, 2.97), current endocrine treatment (OR 1.98, 95% CI 1.21, 3.25), and poor body image (OR 0.98, 95% CI 0.98, 0.99) were associated with less sexual activity at present compared to before breast cancer. Conclusion: Treatment with aromatase inhibitor seems to affect sexual health even beyond discontinuation. Several common late effects were associated with sexual inactivity and reduced sexual functioning. To identify BCSs at risk of sexual dysfunction, special attention should be paid to patients treated with aromatase inhibitor or suffering from these late effects.

25 July 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SSSolveig K. Smedsland
Solveig K. Smedsland
KVKathrine F. Vandraas
Kathrine F. Vandraas
RFRagnhild S. Falk
Ragnhild S. Falk
JHJulie Horn
Julie Horn
RRRandi J. Reidunsdatter
Randi J. Reidunsdatter
KRKristin V. Reinertsen
Kristin V. Reinertsen
Purpose: Sexual health is an important aspect of quality of life. Knowledge concerning sexual health in long-term breast cancer survivors (BCSs) is limited. This study compared sexual health in BCSs 8 years after diagnosis with similarly aged controls and examined the impact of menopausal status at diagnosis and systemic breast cancer treatments on sexual health. Methods: Women aged 20–65 years when diagnosed with stage I–III breast cancer in 2011–2012 were identified by the Cancer Registry of Norway (n = 2803) and invited to participate in a nationwide survey. Controls were women from the Trøndelag Health Study (HUNT4). Sexual functioning and sexual enjoyment were measured by the EORTC QLQ-BR23 subscales scored from 0 to 100, and sexual discomfort by the Sexual Activity Questionnaire scored from 0 to 6. Linear regression analyses with adjustments for sociodemographic and health-related variables were performed to compare groups. Differences of ≥ 10% of range score were considered clinically significant. Results: The study samples consisted of 1241 BCSs and 17,751 controls. Sexual enjoyment was poorer (B − 13.1, 95%CI − 15.0, − 11.2) and discomfort higher (B 0.9, 95%CI 0.8, 1.0) among BCSs compared to controls, and larger differences were evident between premenopausal BCSs and controls (B − 17.3, 95%CI − 19.6, − 14.9 and B 1.2, 95%CI 1.0, 1.3, respectively). BCSs treated with both endocrine- and chemotherapy had lower sexual functioning (B − 11.9, 95%CI − 13.8, − 10.1), poorer sexual enjoyment (B − 18.1, 95%CI − 20.7, − 15.5), and more sexual discomfort (B 1.4, 95% 1.3, 1.6) than controls. Conclusion: Sexual health impairments are more common in BCSs 8 years after diagnosis compared to similar aged population controls. During follow-up, attention to such impairments, especially among women diagnosed at premenopausal age and treated with heavy systemic treatment, is warranted.

3 June 2023 in Acta Oncologica
Verified
Journal Article
Closed access
KVKathrine Vandraas
Kathrine Vandraas
KRKristin Valborg Reinertsen
Kristin Valborg Reinertsen
SSSolveig Smedsland
Solveig Smedsland
SBSynne Bøhn
Synne Bøhn
CKCecilie Kiserud
Cecilie Kiserud
HLHanne Cathrine Lie
Hanne Cathrine Lie
Fear of cancer recurrence (FCR) in breast cancer survivors (BCSs) is common, associated with reduced quality of life and effective interventions exist. There are knowledge gaps concerning FCR among long-term, early-stage BCSs and its associations with other late effects. Within a national cohort, we explored these knowledge gaps, with the ultimate aim of improved care for BCSs experiencing long-term FCR. In this cross-sectional study, all BCSs aged 20-65 years with early-stage breast cancer in 2011-2012 (n = 2803), were identified by the Cancer Registry of Norway in 2019 and mailed a survey including the Assessment of Survivor Concerns used to measure FCR. Factors associated with moderate/high FCR (defined as a sum score of ≥ 6 of a possible range 3-12, or a single score on one of the items of ≥ 3) were explored using a three-block regression analyses including relevant sociodemographic-, health- and cancer-related variables. In total, 1311 BCSs were included (47%). Median age at survey was 60 years. Fifty-six % reported moderate-to-high FCR, associated with younger age (OR 0.96, 95% CI 0.95-0.97) and receiving chemo- and endocrine therapy (OR 1.59, 95% CI 1.15-2.20). After adding late effects into the model, FCR remained significantly associated with these variables, in addition to sleep disturbances (OR 1.58, 95% CI 1.18-2.10). In the final block, adding mental distress, FCR remained significantly associated with younger age (OR 0.97, 95% CI 0.96-0.99), receiving chemo- and endocrine therapy (OR 1.14, 95% CI 1.00-1.97), sleep disturbances (OR 1.44, 95% CI 1.08-1.94) and anxiety (OR 2.67, 95% CI 1.38-5.19). FCR was prevalent eight years after early-stage breast cancer. Being younger, receiving intensive treatment, experiencing sleep disturbances and/or anxiety were associated with moderate/high FCR. Addressing FCR should be part of standard follow-up care of long-term BCSs.

30 September 2023 in Cancer
Verified
Journal Article
Open access
SSSolveig K. Smedsland
Solveig K. Smedsland
RFRagnhild S. Falk
Ragnhild S. Falk
KRKristin V. Reinertsen
Kristin V. Reinertsen
CKCecilie E. Kiserud
Cecilie E. Kiserud
MBMette Brekke
Mette Brekke
KVKathrine F. Vandraas
Kathrine F. Vandraas
Background: Long‐term breast cancer survivors (BCSs) may experience several late effects (LEs) simultaneously. This study aimed to identify subgroups of 8‐year BCSs with higher burden of LEs who could benefit from closer survivorship care, explore variables associated with higher symptom burden, and describe how symptom burden may affect general functioning.Methods: All Norwegian women aged 20 to 65 years when diagnosed with stage I‐III breast cancer in 2011 and 2012 were invited (n = 2803). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire/BR23, the Fatigue Questionnaire, Assessment of Survivor Concerns, and Scale for Chemotherapy Induced Long‐term Neurotoxicity were used to assess 10 common LEs and general functioning. Using latent class analysis, subgroups of BCSs with similar burden of LEs were identified. Multinominal regression analysis were performed to examine variables associated with higher symptom burden.Results: The final sample consisted of 1353 BCSs; 46% had low, 37% medium, and 17% high symptom burden. Younger age, short education, axillary dissection, higher systemic treatment burden, higher body mass index, and physical inactivity were associated with higher symptom burden. General functioning scores were lower, and the proportion on disability pension were higher among BCSs in the two most burdened subgroups compared with those in the low burden subgroup.Conclusion: More than half of long‐term BCSs suffered from medium or high symptom burden and experienced impaired general functioning compared with BCS with low symptom burden. Younger age and systemic treatment were important risk factors for higher symptom burden. BCSs at risk of higher symptom burdens should be identified and offered closer and extended survivorship care.

13 September 2022 in Annals of Oncology
Verified
Journal Article
Closed access
SSS.K. Smedsland
S.K. Smedsland
RFR.S. Falk
R.S. Falk
KVK. Vandraas
K. Vandraas
CKC.E. Kiserud
C.E. Kiserud
MBM. Brekke
M. Brekke
KRK.V. Reinertsen
K.V. Reinertsen

15 February 2022 in Cancer Research
Verified
Journal Article
Open access
SSSolveig Katrine Smedsland
Solveig Katrine Smedsland
KVKathrine Vandraas
Kathrine Vandraas
SBSynne Bøhn
Synne Bøhn
ADAlv A. Dahl
Alv A. Dahl
CKCecilie Kiserud
Cecilie Kiserud
KRKristin Reinertsen
Kristin Reinertsen
Background: Sexual challenges are frequently reported by breast cancer survivors (BCSs). The treatment and associated side effects may all contribute to sexual problems in BCSs. Knowledge concerning sexual activity and functioning among long term BCSs (>5 years after diagnosis) is however limited. The aims of this study were therefore to assess the prevalence of sexual activity and to explore modifiable factors associated with reduced sexual functioning in BCSs 7-8 years after diagnosis, with the ultimate aim of improving follow-up care for BCSs. Methods: The SWEET (survivorship-work-sexual health) study is a cross-sectional nation-wide questionnaire study examining work and sexual health among long-term BCSs in Norway. All women diagnosed with early stage breast cancer (BC) at the age of 20-65 years in 2011 or 2012 without pre- or post- malignancies were identified by the Cancer Registry of Norway (CRN) and invited to study-participation during the fall 2019. Of 2803 BCSs invited, 1361(49%) returned the questionnaire. Of these, 54 were excluded due to incomplete questionnaire, inadequate consent or self-reported BC recurrence, resulting in a final sample of 1307 BCSs. Data were collected using validated questionnaires (Sexual Activity Questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and BR23, Fatigue Questionnaire, The Patient Health Questionnaire-9 and Godin Leisure Time Questionnaire) and questions regarding socio-demography, general health, sleep and cancer treatment. Supplementary cancer related information was obtained from the CRN. Logistic regression analyses examined variables associated with partnered sexual activity. Linear regression analyses examined variables associated with sexual pleasure and sexual discomfort in sexually active BCSs. Results were presented as odds ratio (OR) and beta coefficients (B) with p-values (p). Results: Mean age of BCSs was 51.7 years at diagnosis and 59.7 years at survey. Most participants lived with a partner (74%) and had been treated for BC stage I (45%) or II (36%) with breast conserving surgery (59%), radiotherapy (80%), endocrine therapy (65%) and chemotherapy (69%), while 23 % reported current use of endocrine therapy. Forty-eight percent of the BCSs were sexually active with a partner. Living with a partner (OR 5.2, p<0.001) and having a better body image*(OR 1.01, p<0.001) were positively associated with sexual activity, while older age (OR 0.96, p<0.001) and treatment with aromatase inhibitor (OR 0.58, p=0.002) were negatively associated with sexual activity. Physical activity (B 0.61, p=0.04) was associated with more sexual pleasure, while living with a partner (B -1.68, p<0.001) and experiencing a major depression (B -1.04, p 0.046) were associated with less pleasure. Obesity (B -0.63, p=0.005) was associated with less sexual discomfort, while living with partner (B 0.87, p<0.001), treatment with aromatase inhibitor (B 0.61, p=0.003), sleep problems (B 0.37, p=0.03), breast symptoms* (B 0.01, p=0.01) and chronic fatigue (B 0.43, p=0.03) were associated with more discomfort. Conclusion: Almost 50% of BCSs were sexually active 7-8 years post diagnosis. Several modifiable factors associated with sexual challenges were identified, including a negative body image, physical inactivity, major depression, sleep problems, breast symptoms and chronic fatigue. In the follow-up of BCSs experiencing sexual problems, these factors should be assessed and handled appropriately. BCSs treated with aromatase inhibitor should be offered treatment for gynecological symptoms and a switch to tamoxifen may be discussed. *continuous variable with scale 0-100 Citation Format: Solveig Katrine Smedsland, Kathrine Vandraas, Synne Bøhn, Alv Dahl, Cecilie Kiserud, Mette Brekke, Ragnhild Falk, Kristin Reinertsen. How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-11-05.